Published in Gene Therapy Weekly, September 12th, 2002
Advexin is a treatment for head and neck cancer. The EMEA is the European regulatory organization responsible for the approval of new drugs and biologics in Europe and is the European equivalent of the United States Food and Drug Administration (FDA). Currently, Introgen is enrolling head and neck cancer patients in two global phase 3 clinical trials in the United States and Europe.
Introgen also announced that the European filing will be submitted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.